Loading current stock analysis…
Loading current stock analysis…
India
As of 12 Oct 2026, 03:30 pm
As of October 9, 2026, CARE Ratings reaffirmed Max Healthcare Institute's long-term bank facilities at CARE AA+ with a Stable outlook and short-term bank facilities at CARE A1+. The long-term facilities were increased to ₹1,818.88 crore from ₹1,296.02 crore.
As of October 12, 2026, the daily and weekly trends for Max Healthcare are indicated as 'bearish' based on technical indicators like ADX, DI, and Supertrend direction. The monthly trend, however, is indicated as 'bullish'.
As of October 12, 2026, the nearest support level for Max Healthcare is ₹855.50, which is 1.21% below the current price. The nearest resistance level is ₹869.65, which is 0.43% above the current price.
As of October 12, 2026, Max Healthcare's stock has shown the following period returns: -2.0% for 1 day, -16.6% for 1 month, -21.9% for 3 months, -9.2% for 6 months, -25.1% for 1 year, and -17.5% year-to-date. The return since the start of trading is -24.0%.
As of 12 Oct 2026, 03:30 pm
Recent drawdown or price variability is materially high and may lead to larger short-term outcomes.
Primary driver: Price remains materially below a previous peak
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Trading activity was substantially higher than usual and the price closed lower.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
Latest complete financial results for Q1 FY2027 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹2,366.17 crore | ₹2,142.89 crore | ₹2,067.52 crore | ₹2,135.47 crore | ₹2,027.57 crore |
| Finance Costs | PEAK₹71 crore | ₹66.66 crore | ₹59.67 crore | ₹53.92 crore | ₹54.85 crore |
| Profit Before Exceptional Items And Tax | ₹436.31 crore | PEAK₹464.58 crore | ₹412.78 crore | ₹446.03 crore | ₹400.43 crore |
| Profit Before Tax | ₹436.31 crore | PEAK₹464.58 crore | ₹364.54 crore | ₹446.03 crore | ₹400.43 crore |
| Tax Expense | ₹113.35 crore | PEAK₹122.36 crore | ₹63.62 crore | -₹45.27 crore | ₹92.46 crore |
| Profit Loss For Period | ₹322.96 crore | ₹342.22 crore | ₹300.92 crore | PEAK₹491.30 crore | ₹307.97 crore |
Revenue from operations of ₹2,366 crore was the highest in the last five quarters. The 10.4% sequential increase followed a 3.6% rise in the prior quarter, marking an acceleration in growth. On a year-over-year basis, revenue expanded 16.7%, continuing its upward trajectory.
Total expenses grew 15.0% sequentially. In the current quarter, the following expense categories were recorded: net purchases of stock in trade adjusted for inventory changes at ₹513 crore, employee benefits at ₹388 crore, finance costs at ₹71 crore, and depreciation and amortisation at ₹132 crore. These four items together accounted for approximately 57% of total expenses. The remaining 43% consists of other operating costs.
Finance costs reached ₹71 crore, up 6.5% from the previous quarter and 29.4% from a year ago. This marks the third consecutive quarterly increase in the reported series.
Disclosed bulk and block transactions involving Max Healthcare Institute, shown for the latest 90 days.
Exchange disclosures and regulatory announcements for Max Healthcare Institute.
CARE Ratings reaffirmed Max Healthcare Institute's long-term bank facilities at CARE AA+; Stable and short-term bank facilities at CARE A1+. The long-term facilities were enhanced to ₹1,818.88 crore from ₹1,296.02 crore. The rating action was communicated on October 8, 2026, and disclosed under Regulation 30 of SEBI LODR on October 9, 2026. This is a credit rating reaffirmation with no change in outlook or default risk, affecting the company's debt facilities. Materiality: low.
Max Healthcare Institute Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating
Max Healthcare Institute Limited received a certificate from its registrar, MUFG Intime India Private Limited, confirming that no dematerialization requests were received during the quarter ended September 30, 2026, as the company has no physical shares. The certificate was submitted to the National Stock Exchange of India and BSE Limited on October 7, 2026, under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This is a routine compliance notice with no substantive event or financial impact disclosed.
MAX HEALTHCARE INSTITUTE LIMITED has informed the Exchange about Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B) |SUBJECT: Pendency of any litigation(s) or dispute(s)-(Sub-para 8-Para B)
Max Healthcare Institute Limited has closed its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half-year ending September 30, 2026. This closure is implemented in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Conduct. The Board Meeting to approve these financial results will be announced at a later date.
Max Healthcare Institute Limited announced a trading window closure starting October 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter and half year ending September 30, 2026.
Max Healthcare Institute Limited has informed the Exchange about Copy of Newspaper Publication for Postal Ballot Notice |SUBJECT: Copy of Newspaper Publication
Recent market and company developments associated with Max Healthcare Institute.
hospital stocks, Apollo Hospitals, Fortis Healthcare
Indian equity markets ended higher for the second straight session on Tuesday, with the Sensex rising 685 points to 73,068 and the Nifty gaining 220 points to 22,776. Falling crude prices, largely in-line quarterly updates and broad-based buying supported the gains, while IT and hospital stocks remained under pressure.
<img border="0" hspace="10" align="left" style="margin-top:3px;margin-right:5px;" src="https://timesofindia.indiatimes.com/photo/134700050.cms" />Wall Street has significantly invested in Indian hospitals, focusing on expanding hospital infrastructure and care capacity. This influx of foreign capital has helped private healthcare providers grow, yet costs are escalating for patients. Medical inflation is alarming, with treatment at private facilities vastly outpacing public healthcare costs. Insurers and hospitals are grappling over rising medical expenses and coverage limitations for patients
Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns over hospitals requiring patients to buy medicines from their own or designated pharmacies.
Hospital stocks, Hospital stocks news, Fortis Healthcare share price, Max share porice, Apollo Hospitals share rpice, Medanta share price, Manipal Health share price
Jefferies has maintained a Buy rating on six hospital stocks, including Apollo Hospitals and Fortis Healthcare, following a sharp correction driven by regulatory concerns over drug and consumable price caps. The brokerage expects strong fundamentals and strategic price adjustments to help limit long-term EBITDA impact.
hospital stocks today, healthcare stocks update, nifty healthcare update, apollo hospitals shares fall, max healthcare shares crash
Sensex Today | Nifty 50 | Stock Market Live Updates: Benchmark indices pared gains from the day’s highs and ended near the day’s lows amid heightened volatility at the start of the new series. Persistent global uncertainty and an intraday spike in Brent crude oil prices kept investors cautious.
Comprehensive Section Breakdown for Max Healthcare Institute
Strategic Vision: Operates a network of private hospitals and healthcare services in India.
• Integrated healthcare ecosystem coordinating facilities, diagnostics, and homecare.
• Hub-and-spoke network model for specialized and regional care.
• Bidirectional EMR integration for diagnostics and homecare services.
• Centralized supply chain sourcing for cost optimization.
For the quarter ended June 30, 2026 (FY2026-27 Q1), Max Healthcare Institute Limited reported revenue of ₹2,366 crore, an increase of 10.4% from the previous quarter and 16.7% from a year ago. Profit before tax fell 6.1% sequentially to ₹436 crore, as total expenses grew at a faster pace. Year-over-year, profit before tax rose 9.0%, but net profit growth was limited to 4.9% due to a higher effective tax rate.
Profit before tax declined 6.1% sequentially to ₹436 crore despite higher revenue. This occurred because total expenses, calculated as revenue minus profit before tax, grew 15.0% from ₹1,678 crore in the prior quarter to ₹1,930 crore. The faster expense growth compressed margins relative to the prior quarter.
Year-over-year, profit before tax grew 9.0%, lagging behind the 16.7% revenue expansion. Net profit fell 5.6% sequentially to ₹323 crore and rose 4.9% from a year ago. The narrower annual net profit increase compared to profit before tax resulted from a higher effective tax rate.
Tax expense decreased 7.4% sequentially to ₹113 crore but increased 22.6% from a year ago. The effective tax rate rose from 23.1% in the first quarter of the prior fiscal year to 26.0% in the current quarter. Other comprehensive income shifted from a ₹1.3 crore gain in the previous quarter to a ₹4.8 crore loss, a negative swing of ₹6.1 crore. This movement reduces total comprehensive income but does not affect net profit. No exceptional items were recorded in the current or prior quarter.
Revenue expanded 10.4% sequentially and 16.7% year-over-year, reaching a new high. Profitability declined sequentially because total expenses grew faster than revenue. Finance costs have risen for three consecutive quarters, contributing to the overall expense increase. On a year-over-year basis, profit grew but at a slower pace than revenue, and net profit growth was further moderated by a higher effective tax rate. The quarter demonstrates that while top-line sales are expanding, rising costs are compressing margins.
Category: Healthcare Services
Operates multi-specialty and quaternary care hospitals providing surgery, oncology, cardiology, neurology, and orthopedics.
Category: Healthcare Services
Provides clinical pathology, biochemistry, hematology, and advanced genetic diagnostics across hospital labs and retail collection points.
Key Products & Services: Max Labs
Category: Healthcare Services
Delivers home nursing, critical care ICU setup, physiotherapy, and medication deliveries.
Key Products & Services: Max@Home
Core Thesis: An integrated healthcare ecosystem coordinates clinical facilities, outpatient diagnostics, and home recovery services.
• Quaternary Hub-and-Spoke Network: Quaternary care hospitals function as high-complexity hubs for advanced treatments, supported by regional spoke clinics for routine care and post-operative follow-ups. • Integrated Diagnostic Sourcing: The Max Labs division provides pathology and imaging services, with systems bidirectionally interfaced with the hospital's EMR for instant data upload. • Post-Discharge Home Care: Max@Home optimizes bed turnaround times by coordinating post-discharge nursing, physical therapy, and remote monitoring, feeding patient vitals back to the EMR. • Centralized Supply Chain Sourcing: A centralized procurement system standardizes pharmaceuticals and medical equipment across all network units to lower unit purchase costs.
Reported ownership for FY2027-Q1 as of 2026-06-30.